title: Imiquimod, molluscum, and the need for a better “best pharmaceuticals for children” act.
authors.affiliation: The Permanente Medical Group, Inc., Pleasanton, CA 94588, USA. kenneth.katz@gmail.com
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Katz
authors.forename: Glenda L
authors.initials: GL
authors.lastname: Swetman
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D000279:Administration, Cutaneous; D000634:Aminoquinolines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002648:Child; D002675:Child, Preschool; D004059:Diffusion of Innovation; D003875:Drug Eruptions / Q000209:etiology; D004345:Drug Industry / Q000331:legislation & jurisprudence; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008297:Male; D008976:Molluscum Contagiosum / Q000097:blood / Q000188:drug therapy*; D017594:Publication Bias / Q000331:legislation & jurisprudence; D016032:Randomized Controlled Trials as Topic / Q000331:legislation & jurisprudence; D017211:Treatment Failure; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000077271:Imiquimod